MedTrace Logo

Can the Femoral Nerve Block be Improved by Ultrasound Guidance?

NCT00696150 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 269

Last updated 2008-06-12

No results posted yet for this study

Summary

Studies have suggested a link with effective pain relief and reduced illness and death in very unwell patients. This study will determine the most effective method of injecting local anaesthetic around the nerves which supply the hip joint. Local anaesthetic will be injected around the hips nerve supply using either ultrasound, loss of resistance or electrical nerve stimulator to guide the positioning of the needle on patients due for elective total hip replacement. The patient will then be observed for 30 minutes and the patient ability to move or feel the upper leg will recorded. A standard anaesthetic and a hip replacement operation will then be performed. Standard pain relief protocols will be used the operation and after the operation. After the operation we will record the amount of morphine used and how happy the patients have been with their treatment at 6 hours after the operation and at 24 hours after the operation. The first day the patient is able to walk on their new hip replacement will also be recorded.

Conditions

Interventions

PROCEDURE

determination of method with highest efficacy (ultrasound or nerve stimulator)

Use of ultrasound to guide the insertion of anterior psoas compartment block

PROCEDURE

nerve stimulator

The use of the nerve stimulator to guide insertion of the anterior psoas compartment block

PROCEDURE

loss of resistance

Use of ultrasound to guide the insertion of anterior psoas compartment block

Sponsors & Collaborators

  • Golden Jubilee National Hospital

    collaborator OTHER_GOV

  • NHS Greater Glasgow and Clyde

    lead OTHER

Principal Investigators

  • Malcolm watson, MB ChB FRCA · NHS Greater Glasgow and Clyde

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2010-07-31
Completion
2010-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00696150 on ClinicalTrials.gov